StreetInsider
Log in to your account:
Log in
Signup
Home
EPS Insider
Event Calendar
Conferences
Classic Site
Upgrade to SI Premium - Free Trial
BioMarin Pharma (BMRN) Announces Enrollment of First BMN 250 Phase 1/2 Patient for MPS IIIB
April 21, 2016 4:34 PM
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) announced that it has enrolled the first patient in a Phase 1/2 trial for BMN ...
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
Categories
Corporate News
FDA
Management Comments
Next Articles
BioMarin Enrolls First Patient in Phase 1/2 Trial of NAGLU Fusion Protein BMN 250 for Treatment of MPS IIIB (Sanfilippo B Syndrome)
April 21, 2016 4:30 PM
FDA Not Changing Etep Stance (SRPT) (BMRN) - Leerink
April 21, 2016 11:22 AM
Spark Therapeutics (ONCE) Sees Sharp Upside
April 20, 2016 11:45 AM
BioMarin Pharma (BMRN) Updates on Vosoritide Phase 2 in Achondroplasia; Evidence of Durability Noted
April 20, 2016 10:40 AM
BioMarin Provides Program Update on Vosoritide in Achondroplasia
April 20, 2016 10:36 AM
BioMarin Pharma (BMRN) Announces Positive Preclinical Data from BMN 270 Phase 1/2 in Hemophilia A
April 20, 2016 8:31 AM
